Improvement of adequate use of warfarin for the elderly using decision tree-based approaches

Methods of Information in Medicine

Volumn 53, Issue 1, 2014, Pages 47-53

  Liu, K E ^a   Lo, C L ^a   Hu, Ya Han ^a  

^a NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

Author keywords

Anticoagulant; Decision support techniques; Decision trees; Health services for the elderly; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ALGORITHM; ANAMNESIS; ARTIFICIAL INTELLIGENCE; BODY WEIGHT; COMORBIDITY; CULTURAL FACTOR; DECISION TREE; DOSE RESPONSE; DRUG INTERACTION; ETHNIC GROUP; FEMALE; HEART FAILURE; HOSPITAL INFORMATION SYSTEM; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; TAIWAN; THYROTOXICOSIS; TOTAL QUALITY MANAGEMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARTIFICIAL INTELLIGENCE; BODY WEIGHT; CLINICAL LABORATORY INFORMATION SYSTEMS; COMORBIDITY; CROSS-CULTURAL COMPARISON; DECISION TREES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ETHNIC GROUPS; FEMALE; HEART FAILURE; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; QUALITY IMPROVEMENT; RISK FACTORS; TAIWAN; THYROTOXICOSIS; WARFARIN;

EID: 84892397445     PISSN: 00261270     EISSN: None     Source Type: Journal    
DOI: 10.3414/ME13-01-0027     Document Type: Article

References (54)

1. ASHP. ASHP statement on the pharmacist's role in clinical pharmacokinetic monitoring. American journal of health-system pharmacy. AJHP: official journal of the American Society of Health-System Pharmacists 1998; 55 (16): 1726-1727.
2. Dunn AS, Wisnivesky J, Ho W, Moore C, McGinn T, Sacks HS. Perioperative management of patients on oral anticoagulants: a decision analysis. Med Decis Making 2005; 25 (4): 387-397.
3. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. Am Fam Physi-cian 1999; 59 (3): 635-646.
4. Setiabudi E, Alwi I, Setiati S. Oral anticoagulant treatment in management of elderly patients with atrial fibrillation [corrected]: is it beneficial or detrimental? Acta medica Indonesiana 2008; 40 (1): 40-47.
5. Colombet I, Bura-Riviere A, Chatila R, Chatellier G, Durieux P, for the P-OATsg. Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis. BMC Health Services Research 2004; 4 (1): 27.
6. Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician 2010; 39 (6): 476-479.
7. Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008; 451 (7179): 716-719.
8. Schelleman H, Chen J, Chen Z, Christie J, Newcomb CW, Brensinger CM, et al. Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans. Clin Pharmacol Ther 2008; 84 (3): 332-339.
9. The International Warfarin Pharmacogenetics Consortium. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med 2009; 360 (8): 753-764.
10. Byrne S CP, Barry A, Graham I, Delaney T, Corrigan OI, editor. Using neural nets for decision support in prescription and outcome prediction in anticoagulation drug therapy. Intelligent Data Analysis in Medicine and Pharmacology (IDAMAP-2000). Berlin, Germany: CVAST; 2000.
11. Solomon I, Maharshak N, Chechik G, Leibovici L, Lubetsky A, Halkin H, et al. Applying an artificial neural network to warfarin maintenance dose prediction. Isr Med Assoc J 2004; 6 (12): 732-735.
12. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A poly-morphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105 (2): 645-649.
13. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 geno type to the anticoagulant response to war-farin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007; 63 (12): 1135-1141.
14. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, et al. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clinica chimica acta; international journal of clinical chemistry 2008; 396 (1-2): 76-79.
15. Ferder NS, Eby CS, Deych E, Harris JK, Ridker PM, Milligan PE, et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of thrombosis and haemostasis: JTH 2010; 8 (1): 95-100.
16. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113 (4): 784-792.
17. Harada T, Ariyoshi N, Shimura H, Sato Y, Yokoyama I, Takahashi K, et al. Application of Akaike information criterion to evaluate warfarin dosing algorithm. Thromb Res 2010; 126 (3): 183-190.
18. Le Gal G, Carrier M, Tierney S, Majeed H, Rodger M, Wells PS. Prediction of the warfarin maintenance dose after completion of the 10 mg initiation nomogram: do we really need genotyping? J Thromb Haemost 2010; 8 (1): 90-94.
19. Martin B, Filipovic M, Rennie L, Shaw D. Using Machine Learning to Prescribe Warfarin. 2010: 151-60.
20. Wells PS, Majeed H, Kassem S, Langlois N, Gin B, Clermont J, et al. A regression model to predict warfarin dose from clinical variables and poly-morphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. Thromb Res 2010; 125 (6): e259-264.
21. Cosgun E, Limdi NA, Duarte CW. High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics 2011; 27 (10): 1384-1389.
22. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The pharmacogenomics journal 2005; 5 (4): 262-270.
23. Riley K. FDA approves updated warfarin (Coumadin) prescribing information. 2007 (updated 06/18/2009 cited 2012 March, 20). Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108967.htm.
24. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research pri-orities. Med Decis Making 2010; 30 (3): 328-340.
25. Bussey HI, Wittkowsky AK, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 2008; 28 (2): 141-143.
26. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91 (1): 87-94.
27. Bertola JP, Mazoyer E, Bergmann JF, Drouet L, Simoneau G, Mahe I. Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thromb Res 2003; 109 (5-6): 287-291.
28. Chatap G, Chaibi P, Giraud K, Sadji F, Vincent JP. Oral anticoagulation in older patients. (Establishment and validation of a new posologic warfarin regimen. Anticoagulation orale du sujet age. Etablissement et validation d'une grille d'adaptation posologique de la warfarine.) Presse Med 2001; 30 (10): 475-480.
29. Franko J, Kish KJ, O'Connell BG, Subramanian S, Yuschak JV. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. J Trauma 2006; 61 (1): 107-110.
30. Oates A, Jackson PR, Austin CA, Channer KS. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998; 46 (2): 157-161.
31. Lebovitz HE, Kreider M, Freed MI. Evaluation of Liver Function in Type 2 Diabetic Patients During Clinical Trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25 (5): 815-821.
32. Ishida K, Ishida H, Narita M, Sairenchi T, Saito Y, Fukutomi H, et al. Factors affecting renal function in 119985 adults over three years. QJM 2001; 94 (10): 541-550.
33. You J, Chan F, Wong R, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate intensity anti-coagulation? Br J Clin Pharmacol 2005; 59 (5): 582-587.
34. Hu Y-H, Wu F, Lo C-L, Tai C-T. Predicting warfarin dosage from clinical data: A supervised learning approach. Artif Intell Med 2012; 56 (1): 27-34.
35. Quinlan JR. C4.5: Programs for Machine Learning. San Mateo, CA: Morgan Kaufmann; 1993.
36. Andrew F. Shorr; Marya D. Zilberberg; Scott T. Micek; Marin H. Kollef. Prediction of Infection Due to Antibiotic-Resistant Bacteria by Select Risk Factors for Health Care-Associated Pneumonia. Arch Intern Med 2008; 168 (20): 2205-2210.
37. Hasan O, Meltzer DO, Shaykevich SA, Bell CM, Kaboli PJ, Auerbach AD, et al. Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med 2010; 25 (3): 211-219.
38. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100 (10): 1043-1049.
39. Prompers L, Schaper N, Apelqvist J, Edmonds M, Jude E, Mauricio D, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. Diabetologia 2008; 51 (5): 747-755.
40. Tu JV, Austin PC, Walld R, Roos L, Agras J, McDonald KM. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. J Am Coll Cardiol 2001; 37 (4): 992-997.
41. Freund Y, Schapire R. A decision-theoretic generalization of on-line learning and an application to boosting. J Comput Syst Sci 1997; 55 (1): 119-139.
42. Iftekharuddin KM, Ahmed S, Hossen J. Multiresolution texture models for brain tumor segmentation in MRI. Conf Proc IEEE Eng Med Biol Soc; 2011. pp 6985-6988.
43. Niu B, Cai YD, Lu WC, Li GZ, Chou KC. Predicting protein structural class with AdaBoost Learner. Protein and peptide letters 2006; 13 (5): 489-492.
44. Stollhoff R, Sauerbrei W, Schumacher M. An Experimental Evaluation of Boosting Methods for Classification. Methods Inf Med 2010; 49 (3): 219-229.
45. Scalzo F, Hamilton R, Asgari S, Kim S, Hu X. Intracranial hypertension prediction using extremely randomized decision trees. Med Eng Phys 2012.
46. Tan P-N, Steinbach M, Kumar V. Introduction to Data Mining. Boston: Addison Wesley; 2006. p 769.
47. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
48. Bellazzi R, Diomidous M, Sarkar IN, Takabayashi K, Ziegler A, McCray AT. Data Analysis and Data Mining: Current Issues in Biomedical Informatics. Methods Inf Med 2011; 50 (6): 536-544.
49. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol 2006; 1 (4): 796-801.
50. Schmucker DL. Liver function and phase I drug metabolism in the elderly: a paradox. Drugs Aging 2001; 18 (11): 837-851.
51. Stiglic G, Kokol P. Discovering Subgroups Using Descriptive Models of Adverse Outcomes in Medical Care. Methods Inf Med 2012; 51 (4): 348-352.
52. Tatro D. Drug interaction facts. St. Louis, MO: Wolters Kluwer Health; 2004.
53. Micromedex Gateway. Truven Health Analytics Inc. (internet) (cited May 1, 2012). Avaliable from: http://www.micromedexsolutions.com/ micromedex2/librarian
54. MIMS USA Drug information System. UBM Medica Inc. (internet) (cited May 1, 2012). Available from: http://www.mims.com/